title: Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL).
authors: Department of Radiation Oncology, Institut Curie, 26 rue d’Ulm, Paris, France. youlia.kirova@curie.net
authors: Youlia M
authors: YM
authors: Kirova
authors: Cyrus
authors: C
authors: Chargari
authors: Malika
authors: M
authors: Amessis
authors: Jean-Paul
authors: JP
authors: Vernant
authors: Nathalie
authors: N
authors: Dhedin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D036101:Cord Blood Stem Cell Transplantation; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C401859:temsirolimus; D020123:Sirolimus